On the upside
Vical (Nasdaq: VICL) licensed its DNA immunization technology and Vaxfectin adjuvant to Bristol-Myers Squibb.
Fourth quarter earnings slipped for Pall (NYSE: PLL) but the results surpassed analyst expectations and the company forecast 2013 results ahead of estimates.
On the downside
Pluristem Therapeutics (Nasdaq: PSTI) priced its public offering of 8 million units. Halcon Resources (NYSE: HK) announced the pricing of a secondary offering of 35 million common shares at the discounted price $7.00 per share.
FirstMerit (Nasdaq: FMER) will acquire Citizens Republic Bancorp (Nasdaq: CRBC) in a stock transaction valued at approximately $912 million.
In the broad market, declining issues outpaced advancers by a margin of nearly 5 to 4 on the NYSE and by nearly 10 to 9 on Nasdaq. The Russell 2000 which tracks small cap stocks eased a fraction to 844.